Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $1 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $2 | $2 | $2 | $1 |
| Operating Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -7.9% | -15.4% | -75.7% | -83.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$1 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$1 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |